Danaher Corp
Close on Nov 2, 2026Market cap $160.26BP/E 40.5Yield –
Danaher Biotechnology — Core Sales Growth by Year
Biotechnology — Core Sales Growth (%) (%)
Danaher Biotechnology — Core Sales Growth: 6.5% in FY2025, up 11.0 pts from a year earlier.
Where the FY2025 figure comes from
Source: Danaher IR — nongaap_2025Q4 ↗
Includes Cytiva and Pall Biotech (consumables, bioprocess filtration/chromatography equipment, and cell culture).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Biotechnology — Core Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.5% | +11.0 pts | Danaher IR — nongaap_2025Q4 ↗ |
| FY2024 | Dec 31, 2024 | -4.5% | +13.5 pts | Danaher IR — nongaap_2024Q4 ↗ |
| FY2023 | Dec 31, 2023 | -18.0% | -24.0 pts | Danaher IR — nongaap_2023Q4 ↗ |
| FY2022 | Dec 31, 2022 | 6.0% | – | Danaher IR — nongaap_ex_veralto ↗ |
Breakdown
What makes up biotechnology — Core Sales Growth
Cite this data
StockData. (2026). Danaher Biotechnology — Core Sales Growth (%), annual FY2022–FY2025 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/core-sales-growth-biotech
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.